Health Condition 1: I10- Essential (primary) hypertension
Conditions
Interventions
Intervention1: Dawaul Misk Motadil Sada for 12 weeks: Dawaul Misk Motadil Sada is a semi-solid compound Unani pharmacopoeial formulation taken from NFUM part III. The semi solid drug has been used by
Sponsors
Research Institute of Unani Medicine
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients of hypertension with SBP 140-179 mm of Hg and DBP 90-100 mm of Hg 2. Ambulatory Blood Pressure Monitoring for at least one day. 3. Willingness to participate in this study.
Exclusion criteria
Exclusion criteria: 1. Patient with SBP >=180 mm of hg and diastolic BP >100 mm of hg and secondary hypertension, 2. Pregnant and lactating females, 3. Females using oral contraceptive pills regularly, 4. Patients taking any other medication affecting blood pressure like NSAIDs, 5. Patients with abnormality in investigations done at baseline (SGPT >105 IU). 6. Obese subjects â?? BMI >30, patients with disorders requiring long term-treatment, e.g., diabetes mellitus, drug addicts, alcoholics /malignancy /epilepsy /CAD/CKD, patients with sinus bradycardia, i.e., pulse rate less than 60/min. 7. Treatment defaulters 8. Life threatening medical problems
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in systolic and diastolic blood pressure levels. To achieve a target blood pressure level that is associated with a lower risk of cardiovascular events.Timepoint: The patients will be assessed clinically at every 2 weeks i.e., at 14, 28, 42, 56, 70 and 84, The subjective and objective clinical observations will be recorded in the follow-up sheet. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events:Such as dizziness, fatigue, or gastrointestinal symptoms. These adverse events should be monitored and reported as secondary outcomes. SUBJECTIVE PARAMETERS: Suda (Headache), Duwar (Vertigo), Khafqan (Palpitation), Kasal (Laziness), Qalaq (Anxiety), Usr al-tanaffus (Breathlessness), Takaddurfiâ??lhawas (Diminished alertness), Ruâ??af (Epistaxis) and Nabz mumtali (Pulsus plenus) should be assessed. Quality of life: Hypertension can impact a persons quality of life, and reducing blood pressure can improve quality of life measures such as physical functioning, mental health, and social functioning. Cost-effectiveness: The cost-effectiveness of hypertension treatments is an important consideration for healthcare decision-making. A study can include a secondary outcome measure that evaluates the cost-effectiveness of a hypertension treatment.Timepoint: 12 weeks | — |
Countries
India
Contacts
Public ContactDr Aamir Yousuf
Regional Research Institute of Unani Medicine (RRIUM), Srinagar
Outcome results
None listed